Metacrine, Inc.
DelistedCIK 1634379fmd_0RPV3WXW69V5M75ZMW1M52XZH9Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2019 to Sep 30, 2022, 13 periods
| Line item | FY2019 | FY2020 | FY2021 |
|---|---|---|---|
| Research and development | 26 | 27 | 45 |
| Total operating expenses | 30 | 37 | 61 |
| Operating income | (30) | (37) | (61) |
| Interest expense | 0 | 1 | 1 |
| Interest and investment income | 1 | 0 | 0 |
| Other non-operating income (expense) | 1 | (1) | (1) |
| Income before taxes | (29) | (37) | (62) |
| Income tax expense | 0 | 0 | 0 |
| Net income from continuing operations | (29) | (37) | (62) |
| Net income | (29) | (37) | (62) |